Arrhythmias, end-stage coronary disease, and idiopathic or inherited cardiomyopathies are all examples of cardiac diseases with inadequate therapeutic options. Gene therapy was initially touted as the potential cure for all of these along with many other diseases. Unfortunately, the initial promise of gene therapy has never been fully realized. Some of the difficulties encountered while developing this new therapeutic include inadequate delivery of the transgene, immune reaction to the vector and/or the transgene, and an inability to sustain gene expression after delivery. This proposal focuses on the problem of transgene delivery, with a goal of developing new methods for efficient, safe and effective delivery of the transgene to all of the cells in the target region. The central hypothesis of this proposal is that a systematic exploration of the variables relevant to delivery, either global or local, will allow development of new tools for successful gene transfer. To explore this hypothesis, we will address three aims: 1) To achieve safe, homogeneous, global gene transfer to the heart by systematically evaluating the role of hemodynamic and physical variables on the efficiency of delivery; 2) To improve the precision of focal myocardial gene transfer by developing methods for anatomical and electrophysiological targeting of the injection; and 3) To improve the safety and efficiency of myocardial gene transfer by manipulation of the gene transfer vector. Successful completion of these aims will bring gene therapy one-step closer to realizing its potential as a cardiovascular therapeutic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
5R01EB002846-02
Application #
6798604
Study Section
Special Emphasis Panel (ZRG1-SSS-2 (55))
Program Officer
Moy, Peter
Project Start
2003-09-05
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$294,300
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Finet, J Emanuel; Wan, Xiaoping; Donahue, J Kevin (2018) Fusion of Anthopleurin-B to AAV2 increases specificity of cardiac gene transfer. Virology 513:43-51
Donahue, J Kevin (2016) Biological Therapies for Atrial Fibrillation: Ready for Prime Time? J Cardiovasc Pharmacol 67:19-25
Panda, Nikhil C; Zuckerman, Sean T; Mesubi, Olurotimi O et al. (2014) Improved conduction and increased cell retention in healed MI using mesenchymal stem cells suspended in alginate hydrogel. J Interv Card Electrophysiol 41:117-27
Wolfram, Julie A; Donahue, J Kevin (2013) Gene therapy to treat cardiovascular disease. J Am Heart Assoc 2:e000119
Donahue, J K (2012) Gene therapy for ventricular tachyarrhythmias. Gene Ther 19:600-5
Greener, Ian D; Sasano, Tetsuo; Wan, Xiaoping et al. (2012) Connexin43 gene transfer reduces ventricular tachycardia susceptibility after myocardial infarction. J Am Coll Cardiol 60:1103-10
Igarashi, Tomonori; Finet, J Emanuel; Takeuchi, Ayano et al. (2012) Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 125:216-25
Greener, Ian; Donahue, J Kevin (2011) Gene therapy strategies for cardiac electrical dysfunction. J Mol Cell Cardiol 50:759-65
Amit, Guy; Kikuchi, Kan; Greener, Ian D et al. (2010) Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 121:2263-70
Sasano, Tetsuo; Kelemen, Kamilla; Greener, Ian D et al. (2009) Ventricular tachycardia from the healed myocardial infarction scar: validation of an animal model and utility of gene therapy. Heart Rhythm 6:S91-7

Showing the most recent 10 out of 19 publications